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Development of a Molecular Gram-Stain Assay for the Diagnosis of Blood
Stream Infections Associated with Sepsis

Douglas Litwin, BS
Supervisory Professor: Heidi B. Kaplan, PhD

ABSTRACT
Sepsis is a serious medical condition resulting from the severe dysregulation of
the immune response that is generally triggered by infection. It affects more than
1.1 million Americans, has an average mortality rate of 30%, and is estimated to
cost $24.3 billion annually. Currently, blood culture followed by Gram-stain
analysis is the gold standard for diagnosing bacterial infections associated with
sepsis. This method generates a high rate of false negative results and, in
general, requires 20 to 48 hr to provide results. Both of these problems are
related to the requirement that the bacterial pathogens grow under defined
laboratory conditions. This delay and lack of accuracy in diagnosis affects the
administration of the correct antimicrobial therapy.
I have designed, developed, and begun to validate a rapid, sensitive, and specific
DNA-based quantitative PCR (qPCR) assay, designated the Molecular Granstain (MGS) assay, to detect bacterial pathogens directly from septic patient
blood samples. This assay also differentiates Gram-positive and Gram-negative
pathogens. Importantly, results from this assay may be used to remove patients
from unnecessary antimicrobial treatment at least 4 days earlier than is currently
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possible, because in less than 5 hr it can be determined that no bacterial
pathogen is present in a blood sample. The use of this assay may provide for
more appropriate antimicrobial administration and decrease antimicrobial
resistance and the related costs.
The MGS assay was designed to include internal checks and balances to provide
more accurate pathogen detection. The assay utilizes a dual amplicon approach
with two probes per amplicon. The presence of any bacterial DNA in a sample is
detected by its ability to hybridize to universally conserved regions of the 16S
rRNA gene. Hybridization to regions specific to Gram-positive and Gramnegative bacterial DNA serves to differentiate these two groups.
Eighteen clinical blood samples from suspected sepsis patients were analyzed
using the MGS assay and compared to results obtained from the Memorial
Hermann Hospital Clinical Microbiology Laboratory’s blood culture and Gramstrain analysis. There was 100% agreement between the two positive blood
cultures. There was 37% agreement between the 16 culture-negative samples
and the MGS assay results. There was 62% non-agreement between the culturenegative samples and the MGS assay results. None of the MGS amplificationnegative results were culture positive, supporting the use of this assay as a
reliable means to make the call to remove patients from antimicrobial treatment.
It is anticipated that the use of this MGS assay will provide an increase in the
standard of septic patient care, resulting in better patient outcomes with more
rapid tailored antimicrobial use for those with bone fide infections and removal of
antimicrobial therapy from those without infection.

!

iv!

TABLE OF CONTENTS
Title Page ................................................................................................................ i
Acknowledgments .................................................................................................. ii
Abstract ............................................................................................................. iii-iv
Table of Contents .............................................................................................. v-vi
List of Illustrations ........................................................................................... vii-viii
List of Tables ........................................................................................................ ix
Introduction ...................................................................................................... 1-13
Materials and Methods .................................................................................. 14-19
1. Determination of relevant organisms ............................................................... 14
2. EMA and PMA treatment ................................................................................. 16
3. Testing the qPCR assay in control blood samples .......................................... 16
4. Collection of clinical blood samples ................................................................. 17
5. Isolation of DNA from blood samples .............................................................. 18
6. qPCR of DNA from blood samples .................................................................. 19
Results ........................................................................................................... 20-67
1. 16S rRNA gene determination of areas of interest .......................................... 21
2. Probe design .................................................................................................... 24
3. Primer design ................................................................................................... 31
4. SYBR Green qPCR analysis of primers .......................................................... 33
5. Testing probes on Gram-positive and Gram-negative genomic DNA .............. 37
6. EMA decontamination treatment ..................................................................... 48
7. Synthesis and testing of phosphorothioate blocking oligonucleotides ............. 50

!

v!

8. Testing Staphylococcus aureus viability with EMA and PMA exposure .......... 55
9. Detection of Staphylococcus aureus DNA in Blood and PBS .......................... 56
10. Detection of Enterococcus faecalis DNA in Blood and PBS .......................... 58
11. Detection of Escherichia coli DNA in Blood and PBS .................................... 60
12. Detection of Pseudomonas aeruginosa DNA in Blood and PBS ................... 61
13. Analysis of clinical samples ........................................................................... 63
Discussion ..................................................................................................... 68-75
Perspectives ........................................................................................................ 76
References .................................................................................................... 77-81
Vita ....................................................................................................................... 82

!

vi!

LIST OF ILLUSTRATIONS
Figure 1: Schematic of the Molecular Gram-stain assay ..................................... 21
Figure 2. Nucleotide alignments of the 16S rRNA genes from the STICU
pathogen list ........................................................................................................ 23
Figure 3. Alignments of the universal probe P16S683U ...................................... 26
Figure 4. Alignments of the Gram-positive probe P16S706P .............................. 27
Figure 5. Alignments of the Gram-negative probe P16S1194N .......................... 29
Figure 6. Alignments of the Gram-positive probe P16S1194P ............................ 30
Figure 7. An electrophoresis gel analysis of different primer pair efficiencies .... 32
Figure 8. Standard curve analysis of upstream primers 16S557(19)F and
16S786(23)R ....................................................................................................... 35
Figure 9. Standard curve analysis of downstream primers 16S945(20)F
and 16S1222(20)R .............................................................................................. 36
Figure 10. Fluorescent detection and standard curve plots for the
upstream Probe 16S683U ............................................................................. 38-39
Figure 11. Fluorescent detection and standard curve plots for the
upstream probe P16S706P ........................................................................... 40-41
Figure 12. Fluorescent detection and standard curve plots for the
downstream probe P16S1194P ..................................................................... 42-43
Figure 13. Fluorescent detection and standard curve plots for the
downstream probe P16S1194N ..................................................................... 44-45
Figure 14. Analysis of competitive binding for downstream probes ............... 46-47
Figure 15. Effects of EMA treatment on qPCR reaction ...................................... 49

!

vii!

Figure 16. . Schematic diagram of the use of phosphorothioate blocking
oligonucleotides ................................................................................................... 51
Figure 17. 5’ to 3’ Phosphodiester linkage and 5’ to 3’ phosphorothioate
linkage … ............................................................................................................. 52
Figure 18. A model of the phosphorothioate barrier to PCR amplification ........... 53
Figure 19. The use of phosphorothioate blocking oligonucleotides to
prevent the generation of large PCR amplicons .................................................. 55

!

viii!

LIST OF TABLES

Table 1: List of the 33 most common bacterial species recovered in the
Memorial-Herman Hospital Surgical Trauma Intensive Care Unit from
2009-2012… ........................................................................................................ 15
Table 2: Molecular Gram-stain assay probe sequences ..................................... 25
Table 3. Primers tested for the amplification efficiency for Molecular
Gram-stain assay… ............................................................................................. 32
Table 4. Detection of Staphylococcus aureus DNA in inoculated blood
samples……… ..................................................................................................... 58
Table 5. Detection of Enterococcus faecalis DNA in inoculated blood
samples……… ..................................................................................................... 59
Table 6. Detection of Escherichia coli DNA ininoculated blood samples ............. 61
Table 7. Detection of Pseudomonas aeruginosa DNA in inoculated
blood samples ...................................................................................................... 63
Table 8. Analysis of clinical blood samples with the Molecular
Gram-stain assay………… .................................................................................. 64!
!
Table 9. Analysis of clinical blood sample pellet compared with plasma ............. 66

!

ix!

INTRODUCTION
The severe dysregulation of the immune system resulting from a bacterial,
fungal, viral, or parasitic blood stream infection is referred to clinically as sepsis
(1-3). Sepsis originates from an isolated infection, which spreads to generate
both a systemic infection and an inflammatory response capable of negatively
affecting organs and tissues distant from the initial infection site (3). Sepsis can
be classified into three types: 1) general sepsis is the presence of a systemic
infection and an inflammatory response, 2) severe sepsis includes organ
dysfunction or hypofusion (decreased blood flow through an organ), and 3) septic
shock includes all of the other symptoms and the persistence of hypotension (low
blood pressure) despite resuscitation (1, 4).
Sepsis is consistently among the 15 most common causes of death in the
United States (5). More than one million Americans are affected by sepsis each
year. The annual health care cost for sepsis treatment increased from $15.4
billion (415,280 cases) in 2003 to $24.3 billion (711,736 cases) in 2007. The
number of cases continues to increase annually (6); the number of sepsis-related
hospital admissions doubled from 2000 to 2008 (7). Sepsis commonly results in
severe morbidity with a high incidence of permanent organ damage (7). Hospital
sepsis is the leading cause of death in the intensive care unit (ICU) and morality
rates are estimated from 40% to 70% (8). Sepsis is of particular concern as it
accounts for approximately 2% of hospital admissions, but comprises 17% of inhospital deaths. The increasing number of sepsis cases is alarming due to the
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increasing treatment costs, and its association with increased antimicrobial
resistance and negative patient outcomes.
Prompt identification of the causative organism in sepsis cases is critical,
as it allows for tailored-antimicrobial treatment. A recent study revealed that
appropriate antimicrobial therapy administration within a patient’s first hour of
documented septic symptoms results in a survival rate of 79.9%. However, each
hour appropriate antimicrobial therapy is delayed results in a 7% increase in
mortality (9). A retrospective study of patient survival rates related to appropriate
or inappropriate antimicrobial initiation found a 5-fold reduction (52% to 10.3%) in
survival when inappropriate antimicrobial therapy was provided (8). Surprisingly,
this study revealed a high rate (20%) of inappropriate antimicrobial
administration. This identifies the need for early and accurate identification of
sepsis-causing pathogens to directly improve patient outcomes. Here,
inappropriate antimicrobial therapy is defined either as the absence of
antimicrobials directed at the causative organism or as the administration of an
antimicrobial to which the causative organism is resistant (10).
The current standard of care for patients presenting signs of sepsis is to
administer broad-spectrum antimicrobials, while waiting for results from the
clinical microbiology laboratory. This treatment is critical to decreasing mortality
when infection is present (9, 11). However, the administration of broad-spectrum
antimicrobials for an extended time presents risks, including secondary infections
and antimicrobial resistance. At least two million Americans are affected each
year by drug-resistant infections and an estimated 23,000 of these patients die
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(12). For example, Clostridium difficile infection (CDI) is a common nosocomial
infection that can cause severe and recurrent diarrhea and is generally acquired
as a result of antimicrobial use. Hospital-administered antimicrobials disrupt the
normal gastrointestinal microbiota and allow this multidrug-resistant pathogen to
colonize and proliferate in the colon, where it produces the toxin that causes
disease. These infections are a serious condition affecting an estimated 250,000
Americans each year and are responsible for at least 14,000 deaths annually
(12).
A CDC report estimates that up to 50% of the antimicrobials used are
unnecessary and lead to antimicrobial resistance (12). It is expected that rapidly
identifying the absence of infection will decrease the inappropriate use of
antimicrobials. Under current practices, clinical microbiology laboratories require
5-7 days to provide information concerning a negative blood sample (i.e. to
determine that no infectious agent is growing in the culture medium). If infectionnegative results were provided 4 to 6 days earlier, patients could be removed
from inappropriate antimicrobial therapy, reducing the many negative outcomes
associated with inappropriate antimicrobial use. The development of a rapid,
accurate, and sensitive method to identify sepsis-associated pathogens would
provide more appropriate antimicrobial administration and decrease antimicrobial
resistance and its related costs.
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Current clinical methods to identify bacterial pathogens
Blood culture and Gram-stain methods
The current blood culturing methods employed by clinical laboratories
focus on the detection of viable organisms. This is useful in that live organisms
are isolated that can be used for antimicrobial susceptibility testing. However,
blood culturing suffers from weaknesses including: 1) ineffective detection of
uncultivable or fastidious pathogens, 2) prolonged time to pathogen identification
due to the requirement that organisms reach approximately 105 colony forming
units (CFU)/ml in culture medium, 3) reduced sensitivity related to the volume of
blood cultured, and 4) a loss of sensitivity when blood culture bottles are not
placed immediately in the instrument (13-20).
The current process of blood culturing involves drawing two or three blood
culture samples at different times and locations, which are directly inoculated into
20 to 30-ml continuous-monitoring blood culture system (CMBCS) bottles, such
as the Bactec 9240 system (Becton Dickinson, Franklin Lakes, NJ), the
BacT/Alert system (bioMerieux, Durham, NC), and the VersaTREK system
(TREK Diagnostic Systems, Independence, OH). The samples are grown and
tested both aerobically and anaerobically (21). The CMBCS systems detect
bacterial growth by monitoring either CO2 production through fluorescence or
colormeteric sensors, or by detecting changes in internal bottle pressures
resulting from gas production (21-23). These bottles also commonly contain
activated carbon (charcoal) or resin to limit the effects of antimicrobial agents
present in the blood (24).
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In general, a sample is detected as ‘culture positive’ by CMBS systems
when the growth reaches between 1 x 105 cells/ml (25, 26). Optimization of the
culture medium and automation of the instrumentation has improved the
diagnostic accuracy of blood culturing. However, the previously mentioned
limitations still persist and some bacterial and fungal species perform differently
in the CMBCS systems (21). Variability has been shown among the CMBCS
systems in time to detection (TTD) and the rate of recovery of organisms in the
presence of antimicrobials (27, 28). One study noted the TTD of bacteria to
ranges from 11.2 to 47.4 hrs depending on the CMBCS system and conditions
used, such as preexisting antibiotic concentrations present in the samples and
aerobic conditions (28). Furthermore, although it is generally accepted that
bacterial concentrations of 105 cells/ml are required for positive identification on
the BacT/ALERT, some organisms, such as Mycoplasma hominis, can grow to
as many as 107 cells/ml in the BacT/ALERT system without being detected as
positive (29).

Gram-stain analysis
After bacterial growth is detected in the CMBCS, the blood culture is
subjected to Gram-stain analysis that is generally performed manually. The
Gram-stain differentiates bacteria by the ability of their cell wall to retain
peptidoglycan-binding crystal violet dye after decolorization with alcohol or
acetone. Those bacterial cells whose walls do not retain crystal violet after
alcohol decolorization are differentiated by staining with the secondary dye,
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safranin. The Gram-positive cells retain crystal violet and appear purple,
whereas the Gram-negative cells retain the safranin dye and appear pink (30).
Gram staining is a quick (<15 min) and inexpensive method for general
phenotypic characterization. However, certain organisms do not react as
predicted to the dyes and thus, give inaccurate results. For example, some
Gram-negative bacteria such as Acinetobacter can resist decolorization and
appear as Gram-positive cells (31). Other organisms, termed ‘acid-fast’, include
mycobacteria that a have a high concentration of lipids in their cell walls, which
make them impermeable to the Gram-strain dyes and cause variable results (32,
33). Additionally, correct analysis of Gram-stain samples is subjective and
requires a high level of experience.

Species identification and antibiotic susceptibility
Currently, clinical microbiology laboratories perform species identification
and test antimicrobial susceptibility on viable organisms recovered from culture
media. Differential media, both liquid and solid, can be used to differentiate
bacterial species based on metabolic characteristics. Selective media allows the
growth of a specific bacterial species while inhibiting others. Automated bacterial
identification and antimicrobial susceptibility determination instruments, such as
the Phoenix 100 (Becton Dickinson) and the Vitek 2 system (bioMerieux),
combine differential and selective media methods with chromogenic and
fluorogenic biochemical tests and broth-dilution antimicrobial susceptibility
methods.
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Specifically, clinical microbiology laboratories evaluate antimicrobial
susceptibility through a variety of methods including broth dilution tests,
antimicrobial gradient tests, disk diffusion tests, selective and differential media
and automated instrument systems (34). Broth dilutions are performed by using
a clinical isolate at ~1X105 CFU/ml to inoculate liquid medium containing two-fold
dilutions of an antimicrobial and determining the minimal inhibitory concentration
(MIC) by visually inspecting the turbidity following overnight growth. The
antimicrobial gradient test, the AB BIODISK (bioMerieux), uses printed
antimicrobial strips that contain an increasing concentration of the antimicrobial
along the length of the strip. The strips are placed onto agar plates that have
been inoculated so that a clinical isolate covers the surface. After incubation the
MIC is determined by evaluating the changing growth pattern along the length of
the antimicrobial strip. Disk diffusion tests are performed by inoculating a clinical
isolate at a concentration of ~1x108 CFU/ml on a Mueller-Hinton agar plate then
placing paper disks containing known concentrations of antimicrobials on the
agar surface. After 16 to 24 hr of incubation, the MIC is determined by
measuring the area of growth inhibition around the antimicrobial disks and
comparing it to standards. Automated instruments are preferred for use in clinical
microbiology laboratories due to the reduced manual labor required and their
reproducibility. However, in general all of these results are not obtained until
about 24 hr after the blood culture is positive due to their requirement for
continued growth of the organism (35).
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Molecular methods to identify bacterial pathogens
Molecular diagnostic methods offer a solution to the problems associated
with pathogen identification requiring the detection of viable organisms.
Molecular methods have advantages in comparison to the traditional culture and
Gram-stain method in that: 1) they are more rapid, 2) pathogens can be identified
and quantitated directly from clinical samples, and 3) they eliminate variability
associated with varying growth requirements for different organisms. Many
molecular pathogen detection techniques have been developed that rely on:
PCR, real-time PCR, mass spectroscopy, microscopy, and nuclear magnetic
resonance (NMR) !
(36-45).

PCR
Many different PCR-based molecular methods for the diagnosis of blood
stream infections have been developed and optimized. LightCycler SeptiFast
(Roche Diagnostics, Indianapolis, IN), SepsiTest (Molzym Corp., Bremen ,
Germany), and VYOO (SIRS-Lab, Jena, Germany) are the three assays most
widely used outside of the U.S. No methods are currently approved by the FDA
that use molecular methods to directly identify bacteria from blood samples.
Other methods in development and testing include PCR coupled with mass
spectroscopy (39).
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LightCycler SeptiFast
The LightCycler SeptiFast (LC-SF) test developed by Roche Diagnostics
was the first real-time PCR test designed to detect bacteria and fungi directly
from blood samples with no incubation period. This test uses real-time PCR
FRET probes to identify the 14 most common bacterial and six most common
fungal pathogens. The details of the probes and assay are proprietary; however,
it is known that the probes target the internal transcribed regions of the bacterial
16S and 23S rRNA genes and the fungal 18S and 5.6S rRNA genes. Blood
samples are extracted using an automated DNA extraction instrument and
assayed using a sample capillary real-time PCR instrument. Studies have shown
that this method is faster and more accurate than current culturing methods for
the identification of fungal and bacterial species (36-38).

SepsiTest
The SepsiTest is a standard PCR test using multiplexed primers that
amplify regions of either Gram-positive or Gram-negative 16S rRNA genes or
regions of fungal 18S rRNA genes. Each primer set produces a band unique to
Gram-positive bacteria, Gram-negative bacteria or fungal pathogens. PCR
products are then analyzed by gel electrophoresis and distinctive bands are gel
extracted and subjected to DNA sequencing. This test is designed to detect 375
pathogenic organisms, most of which are bacteria (40). Studies have shown that
this test is rapid and accurate when on-site DNA sequencing is available.
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However, it requires a substantial amount of manual labor and requires an
experienced technician for PCR and DNA sequence analysis (41).

VYOO
The VYOO test developed by SIRS-Lab is a multiplexed standard PCR
assay designed to identify bacterial and fungal pathogens and several resistance
genes. The assay uses an affinity resin to enrich the pathogen DNA from a
clinical sample followed by PCR amplification using proprietary primer sets that
are specific to 33 bacteria, five resistance genes, and seven fungal species. The
PCR products of different sizes are then analyzed by gel electrophoresis (42).
Studies have shown high variability in the sensitivity of this method and it
requires significant manual processing time (43).

MALDI-TOF
Matrix-assisted laser desorption/ionization-time-of-flight mass
spectrometry (MALDI-TOF MS) is the process by which molecules are ionized
and then detected after being separated by charge and mass (39). MALDI-TOF
MS is most useful for the identification and quantification for proteins and other
biomolecules. This technology has been adapted for the identification of
biomarkers associated with many medical conditions (44). It has a high rate of
accuracy in diagnostic capability in clinical laboratory settings. However, when
analyzing complex samples such as blood, sample enrichment steps (preculture) are required and this adds additional time to identification of causative
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organisms. The cost is also of concern. MALDI-TOF MS instruments typically can
cost as much as $180,000 and require a skilled technician (39, 45).

Microscopy
Fluorescent in situ hybridization (FISH) coupled with automated
microscopy has recently been evaluated for identification of seven known
bacterial species grown in simulated blood cultures using the BD BACTEC
(Becton Dickinson). This method is ‘multiplex compatible’ and has high
sensitivity (97 to 99%). However, its ability to replace the downstream analysis of
current blood culturing methods is currently undetermined. Thus, this technique
has the same problems as the current clinical culturing methods, including time
to identification and that a high cell concentration is needed for detection (46).
The use of automated microscopy to identify Staphylococcus aureus and
Pseudomonas aeruginosa from clinical bronchoalveolar lavage (BAL) samples
has been successful. This technique uses automated microscopy to analyze
bacterial cells immobilized on a microfluic chip. The bacterial cells are initially
given a negative charge through a wash step with electrokinetic buffer (47). The
bacterial cells are then inserted into the microfluidic chip and driven toward a
poly-cationic poly-L-lysine coating on the opposite side of the chip by an electric
charge. The cells stick to the poly-cationic poly-L-lysine coating after the charge
is removed. An automated microscopy system then tracks the actively growing
cells and analyses their mass, geometry and growth rate (47). This technique is
unique and performed well under the limited conditions in which it was tested.
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However, it still relies on bacterial growth and has been tested on only a few
organisms.

NMR
A recently developed technique utilizing magnetic nanoparticles (MNPs)
and miniaturized NMR (µNMR) instrumentation has been developed for pathogen
detection in clinical microbiology labs (T2 Biosystems, Lexington, MA). This
technique uses asymmetric reverse transcription PCR targeting the 16 rRNA
transcripts to generate signal-stranded DNA that are subsequently bound by
bead-capture probes. The DNA-probe complexes have overhangs of non-bound
DNA. These overhangs are targeted by MNP-detection probes. Once bound, the
MNP-detection probes decrease the transverse relaxation rate of a sample that is
measured on a µNMR instrument. This technology has shown promise as a
clinical tool due to its high sensitivity and accuracy (48).

The Molecular Gram-stain Assay
We have designed a molecular method, termed the Molecular Gram-stain
(MGS) assay, utilizing quantitative real-time PCR for detection of bacterial
pathogens directly from blood samples. The pathogens are differentiated as
either Gram-positive or Gram-negative. The assay includes internal checks and
balances to ensure rapid, sensitive, and quantitative pathogen detection.
This assay is unique in that it was designed to detect essentially all
bacterial pathogens and to differentiate them based on their Gram status. A
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double amplicon approach generates two separate PCR targets within the
bacterial 16S rRNA gene with two fluorescent probes targeting each amplicon.
The output data determine if the probes target Gram-positive or Gram-negativespecific and/or universal regions. This 16S rRNA gene-based assay should
prove critical for the treatment of septic patients, as it will determine if a blood
sample is infected with bacteria or not. Rapidly determining the presence or
absence of bacteria in a blood sample will inform the decision to maintain
antimicrobial therapy or to discontinue its use. The ability of the assay to
differentiate between Gram-positive and Gram-negative pathogens will also
suggest more specific treatment, as more tailored antimicrobials can then be
prescribed. Identifying bacteria universally and by Gram-status a major
advantage over the other molecular techniques available that identify pathogens
within a predefined group and thus cannot rule out bacterial infection if the
causative organism is not one of the target organisms.
A key component of the MGS assay is the use of minor-groove binding
(MGB) Taqman fluorescent probes (49). MGB probes are oligonucleotide
hydrolysis probes that include a 3’ dihydrocyclopyrroloindole tripeptide (DPI3).
When attached to DNA probes, DPI3 peptides bind the minor groove of the
complementary target strand upon duplex formation. DPI3 binding increases the
melting temperature and the specificity of probe hydrolysis. MGB probes are
capable of discriminating single nucleotide mismatches in their target region,
which is critical for differentiating regions in highly conserved genes, such as the
bacterial 16S rRNA gene (49).
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MATERIALS AND METHODS
Determination of relevant organisms
A list of 33 bacterial species isolated from positive blood cultures in the surgical
trauma intensive care unit (STICU) from 2009-2012 at Memorial Herman Hospital was
obtained from the STICU pharmacy (Table 1). An additional group of 90 bacterial
species assembled for an osteomyelitis study performed previously in our laboratory,
was used for in silico analysis to test the extent of our probe coverage for general
bacterial pathogens.
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GRAM%NEGATIVE+

GRAM%POSITIVE+

Rank+

Species+

Frequency+

Rank+

Species+

Frequency+

Rank+

Species+

Frequency+

1.!

Escherichia)
coli)

11!

1.!

Staphylococcus)
not)aureus)

28!

7.!

Streptococcus)
pneumoniae)

1!

2.!

Bacteroides)
fragilis)

10!

2.!

10!

7.!

Streptococcus)
species!

1!

3.!

Enterobacter)
cloacae)

7!

3.!

Enterococcus)
faecalis)

7!

7.!

Vancomycin;
resistant!
Enterococcus!

1!

3.!

Klebsiella)
pneumoniae)

7!

4.!

Methicillin8
resistant)
Staphylococcus)
aureus)

6!

4.!

Pseudomonas)
aeruginosa)

7!

5.!

Alpha)
streptococci)

5!

5.!

Serrratia)
marcesens)

6!

6.!

Bacillus)sp.)

2!

6.!

Acinetobacter)
baumannii)

5!

6.!

Gamma)
streptococci)

2!

6.!

Acinetobacter)
lwoffi)

1!

6.!

Group!A!beta)
streptococci)

2!

6.!

Citrobacter)
koserii)

1!

7.!

Group!C)
streptococci)

2!

6.!

Eikenella)
corrodens)

1!

7.!

Bacillus)cereus)

1!

6.!

Enterobacter)
aerogenes)

1!

7.!

Cornybacterium)

1!

6.!

Enterobacter)
asburiae)

1!

7.!

Group!B)
streptococci)

1!

6.!

Prevotella)

1!

7.!

Group!F)
streptococci)

1!

6.!

Proteus)
mirabilis)

1!

7.!

Group!G)
streptococci)

1!

6.!

Salmonella)

1!

7.!

Peptostreptococc
cus)

1!

Methicillin8
sensitive)
Staphylococcus)
aureus)

!

Table 1: List of 33 bacterial species isolated from clinical blood samples in
the Memorial-Herman Hospital Surgical Trauma Intensive Care Unit from
2009-2012. Species are grouped by Gram status and listed by the frequency of
recovery for the 134 samples analyzed.
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+
EMA and PMA treatment
Pretreatment of solutions containing the appropriate master mix and primers with
either ethidium monoazide (EMA) or propidium monoazide (PMA) was required to
eliminate contaminating bacterial DNA present in the solutions. EMA and PMA
covalently intercalate into double-stranded DNA upon exposure to light. The PCR and
qPCR master mixes used were either QuantiFast probe master mix or QuantiFast Sybr
green master mix (QIAGEN, Valencia, CA). Stock solutions of EMA and PMA at 239
µM and 20 mM, respectively were stored at -20°C in the dark. In the presence of
reduced light, EMA was added to the previously prepared master mix to a final
concentration of 9 µM. The solution was mixed briefly by repeat pipetting, incubated at
room temperature for 5 min, and exposed to a 500 watt light (Gulo Model A) from a
distance of 10 cm for 5 min while on ice. The appropriate probes, (10 µM in EMAtreated H2O) were added to a final concentration of 0.25 µM while the solution remained
on ice. The same procedure was performed for the PMA treatment (20 µM final
concentration) of phosphate buffered saline (PBS).

Testing the qPCR assay in artificially inoculated blood samples
Blood was drawn from healthy volunteers into 4.5-ml citrate-containing
Vacutainer tubes (Becton Dickinson). Aliquots (1 ml) of the blood were placed
into 1.5-ml microcentrifuge tubes. Cultures (10 µl) of Staphylococcus aureus,
Enterococcus faecalis, Pseudomonas aeruginosa and Escherichia coli at
concentrations two logs higher than the desired final concentration in the blood
sample were added to the 1-ml aliquots to give final concentrations ranging from
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101-105 CFU/ml. Those blood samples were then centrifuged at 13,000 x g for 2
min, the plasma (upper phase) was removed and both fractions (the blood pellets
and plasma) were stored at -20°C until analysis. Similar samples were also
prepared in 1-ml of 20 µM PMA-treated PBS, by adding 10 µl of the bacterial
culture (two logs higher than the desired concentration) and 2 µl of yeast
genomic DNA (500 ng/µl) to a sterile 1.5-ml microcentrifuge tube. The samples
were stored at -20°C until analysis. The total DNA was later extracted using the
Mo-Bio Bacteremia kit (MO BIO Laboratories, Carlsbad, CA). Both the PBS-PMA
and blood pellet extracted samples were analyzed using the MGS assay.

Collection of clinical blood samples
The clinical blood samples were drawn in sodium citrate-containing
Vacutainers by nurses in the Memorial-Herman Hospital’s STICU and Burn Unit
based on a physician’s diagnosis of a presumed septic patient. Patients are
evaluated for sepsis based on the severe inflammatory response syndrome
(SIRS) criteria. The SIRS criteria are: 1) a temperature 1+-37°C, 2) a heart rate
> 90 beats per min, 3) a reparatory rate > 20 breaths per min, and 4) an increase
or decrease in white blood cell count (1). A patient showing signs of two or more
of the SIRS criteria are presumed to be septic. The Vacutainers were maintained
at room temperature until they were collected, given a sample number
associated with the patient ID number (de-identified), and transferred to the
research laboratory by a laboratory manager, generally within 12 hr of the blood
draw. Aliquots (1 ml) of the blood from the Vacutainer were transferred into
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labeled sterile 1.5-ml microcentrifuge tubes, centrifuged at 13,000 x g for 2 min.
The upper phase (plasma) was then removed without disturbing the blood pellet
and transferred to a sterile 1.5-ml microcentrifuge tube. The blood pellets,
plasma and remaining Vacutainer tubes were then stored at -20°C until analysis.

Isolation of DNA from blood samples
DNA was isolated from blood and plasma samples using the Mo-Bio
BiOstic® Bacteremia DNA Isolation Kit (MO BIO Laboratories) according to the
manufacturer’s recommended protocol, except that all of the reagents were
pretreated with EMA. Briefly, the blood pellet was thawed and resuspended in
CB1 solution (450 µl), transferred into a 2-ml microbead tube, briefly vortexed
and heated to 80°C for 15 min. The tubes were horizontally secured onto a Mobio Vortex-Genie® attachment and vortexed at maximum speed for 10 min. The
tubes were centrifuged at 10,000 x g for 1 min and the supernatant was
transferred to a new 1.5-ml microcentrifuge tube. The CB2 solution (100 µl) was
added and the samples were vortexed briefly. The samples were incubated at
room temperature for 5 min and then centrifuged at 10,000 x g for 1 min. The
supernatant was transferred to a new 1.5-ml microcentrifuge tube. The CB3
solution (1 ml) was added and mixed by repeat pipetting. A portion of the
solution (600 µl) was then added to a spin filter column and centrifuged at 10,000
x g for 1 min. The flow-through was discarded. This step was repeated until the
entire sample was passed through the column. The column was transferred to a
new collection tube and washed twice with CB4 solution (600 µl) and centrifuged
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at 10,000 x g for 1 min. The column was centrifuged at 13,000 x g for 3 min to
dry the column. The DNA was eluted using CB5 solution or H2O (50 µl). The
plasma samples were treated identically, except that twice the volume was used
because of their larger volume.

qPCR of DNA from blood samples
The qPCR master mix contained QuantiFast Probe PCR +ROX Vial Kit (QIAGEN
Valencia, CA), forward and reverse primers (0.5 uM) and H2O. The complete master
mix was treated with EMA (at a final concentration of 9 uM). Probes that were
previously diluted to 10 uM in EMA-treated H2O were added after the EMA treatment.
Aliquots (15 ul) of the completed master mix were placed into each well of a standard
96-well polypropylene qPCR plate (Denville Scientific Inc. Metuchen, NJ). The samples
were analyzed in duplicate and standards were used in concentrations representing 101
to 105 cell/ml. The qPCR cycling conditions used were based on the manufacturer’s
recommendation: 1) initial denaturation step of 95°C for 3 min, 2) denaturation step of
95°C for 10 sec, 3) annealing step of 58°C for 5 sec, and 4) extrusion step of 60°C for 1
min. Steps 2-4 were repeated 40 times.
The qPCR samples were analyzed using the Applied Biosystems 7000 system
software (Life Technologies, Grand Island, NY). Quantitation of unknown samples was
automatically calculated by standard curve comparison of Ct values generated from S.
aureus or E. coli DNA depending on the Gram-status.
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RESULTS

The identification of sepsis-associated infections by molecular methods
has great potential for improving patient outcomes (50). The most common
method used to identify bacterial pathogens in clinical microbiology laboratories
today is blood culture followed by Gram-stain analysis. Although this has clinical
utility, it suffers from many shortcomings. The major problems are a lack of
sensitivity and prolonged time to detection of the causative organisms (13-18, 20,
29). Recently developed molecular techniques have focused on the identification
of pathogens by mass spectroscopy, microscopy, NMR and PCR-based
technology (36-48).
We have designed, developed, and begun to validate a quantitative realtime PCR method for rapid, sensitive, and quantitative pathogen detection in
blood samples from septic patients. Specifically, this method, termed the
Molecular Gram-stain (MGS), can determine the Gram-status of a pathogen in a
blood sample within 4.5 hr. The use of minor groove binding probes makes it
possible to have high binding fidelity with short target sequences. The MGS
assay was designed to couple these highly specific probes with internal checks
and balances. Specifically, the MGS assay amplifies two regions of the bacterial
16S rRNA gene, which I term the ‘upstream and downstream amplicons’. Two
probes, a universal and a Gram-positive probe, target the upstream amplicon
and two probes, a Gram-negative and Gram-positive probe, target the
downstream amplicon (Fig. 1). By using this dual amplicon approach, the assay
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Molecular Gram Stain Assay
Primer and probe design summary:
1. Designed two sets of primers (upstream and downstream) that bind to the regions
conserved among all bacteria
detects bacterial pathogens and differentiates them by Gram-status with
2. Designed two sets of probes for each amplified area (PCR product).
a. Upstream PCR product: Universal probe and Gram-pos probe
redundancy.
b. Downstream PCR product: Gram-neg probe and Gram-pos probe
3. Currently each probe in a pair are labeled with a different fluorophore.
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Figure 1. Schematic of the Molecular Gram-stain assay. The MGS
assay targets the bacterial 16S rRNA gene. The upstream amplicon is
comprised of primers and probes: 16S557(19)F, 16S786(23)R,
P16S683U, and P16S706P. The downstream target is composed of
primers and probes: 16S945(20)F, 16S1222(20)R, P16S1194P, and
P16S1194N.

Primer and probe design
+
Determination of areas of interest within the 16S rRNA gene
The bacterial 16S rRNA gene was chosen as the target of the MGS assay
because it is present in all bacteria in single or multiple copies and is composed of
conserved and variable regions that can be used to differentiate genera and species
(51, 52). These genes are especially useful for probe-based qPCR assays because the
conserved regions function in the amplification the variable regions, which can serve as
unique targets for differentiation by DNA probes. To identify the best regions to serve
as probe targets, up to three 16S rRNA genes, chosen at random from most of the 33
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common pathogens detected in septic patients in the Memorial Hermann Hospital
STICU, were aligned using the Geneious software suit’s (Biomatters Limited, San
Francisco, CA) CLUSTAL nucleotide alignment algorithm. The nucleotide alignments of
the relevant organisms were evaluated for use as probe target regions. Three types of
conserved regions were identified (Fig. 2): one universally conserved, two conserved
among the Gram-positive species, and one conserved among the Gram-negative
species.
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Figure 2. Nucleotide alignments of the 16S rRNA genes from the
Memorial Hermann Hospital STICU pathogen list. Species are grouped
as Gram-positive (upper panel) and Gram-negative (lower panel). The
areas identified as ideal targets for Gram-positive identification are shown
in blue. The area identified as an ideal target for Gram-negative
identification is shown in orange. An area identified as an ideal target for
universal bacterial identification is shown in green.
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Probe design
To select specific areas highly conserved among the 18 Gram-positive
pathogens, the sequences were aligned and compared to same region in the 15 Gramnegative pathogens. The same analysis was performed to select areas highly
conserved among the Gram-negative pathogens. Areas unique to either Gram-positive
or Gram-negative pathogens were selected and evaluated for probe parameters using
the AlleleID software suit (PREMIER Biosoft, Palo Alto, CA). Regions universally
conserved (common to both the Gram-positive and Gram-negative pathogens) were
also evaluated. One Gram-negative, one universal and two Gram-positive probes listed
below (Table 2) were identified that met our criteria. These criteria included: 1) the
region spanned at least 13 nucleotides that maintained 90-100% homology among all of
the Gram-positive, Gram-negative, or all of the species in the alignments, 2) the
sequence had more cytosines than guanines and no 5’ guanine, and 3) at least one
discriminatory mismatch was located near the 3’ terminus. The number of guanines is
critical because they can act as a fluorescence quencher, which suppresses the
fluorescent signal available for detection in the qPCR reaction, and guanine-guanine
interactions can interfere with probe annealing.
One region approximately 100% conserved among all the species and
one region slightly downstream, which is 100% conserved among the Grampositive species were identified (Table 2 and Fig. 3, 4). The region conserved
among Gram-positive species is of particular interest in that it had two or more
!
!
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Upstream Probes
P16S683U
P16S706P

Probe Sequence (5’-3’)
6FAM-TTTCACCGCTACAC-MGBNFQ
NED-ATATGGAGGAACACC-MGBNFQ

Downstream Probes
P16S1194N
P16S1194P

Probe Sequence (5’-3’)
6FAM-TCAAGTCATCATGG-MGBNFQ
NED-TCAAATCATCATGC-MGBNFQ

Table 2: Molecular Gram-stain assay probe sequences. Probe
sequences are listed in pairs for the upsteam amplicon and downstream
amplicons. P16S683U is a universal probe that should detect all bacterial
16S rRNA genes. P16S706P and P16S1194P are Gram-postive-specific
probes. P16S1194N is a Gram-negative-specific probe. All probes have a
5’ fluorophore (6FAM or NED) and a 3’ minor-groove binding motif and
non-fluoresent quencher (MGBNFQ).+
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Figure 3. Alignments of the universal probe P16S683U. (A) The P16S683U
probe aligned with Gram-negative species. (B) The P16S683U probe aligned
with Gram-positive species. Nucleotide mismatches with the probe sequence are
shown in bold in the alignment.
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Figure 4. Alignments of the Gram-positive probe P16S706P. (A) The
P16S706P probe aligned against Gram-negative species. (B) The P16S706P
probe aligned against Gram-positive species. Nucleotide mismatches with the
probe sequence are shown in bold in the alignment.
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nucleotide mismatches with all of the Gram-negative species (Table 2 and Fig.
4). After verifying that they fit our criteria for probe design, both regions were
aligned with the 16S rRNA gene from E. coli O104:H4 and named according to
the E. coli nucleotide number at which the most 5’ end of the probe aligned:
universal probe P16S683U and Gram-positive probe P16S706P.
The next region identified was of particular interest because it maintained
a high degree of homology among all of the species, except that there were two
nucleotide mismatches between all of the Gram-positive and all Gram-negative
species, one of which was located at the 3’ end. Mismatches on the 3’ end have
been shown to have the greatest discriminatory capabilities (49). This region
was aligned on the 16S rRNA gene from E. coli O104:H4 and the probe with
close to 100% homology to the Gram-negative species was designated
P161194N. The probe with 100% homology to the Gram-positive species was
designated P161194P (Table 2 and Fig. 5, 6).
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Figure 5. Alignments of the Gram-negative probe P16S1194N. (A) The
P16S1194N probe aligned against Gram-negative species. (B) The P16S1194N
probe aligned against the Gram-positive species. Nucleotide mismatches with
the probe sequence are shown in bold in the alignment.
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Figure 6. Alignments of the Gram-positive probe P16S1194P. (A) The
P16S1194P probe aligned against Gram-negative species. (B) The P16S1194P
probe aligned against the Gram-positive species. Nucleotide mismatches with
the probe sequence are shown in bold in the alignment.
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Primer design
The 100 bp regions flanking the probe target regions were evaluated for
primer selection. The criteria for suitable primers were: 1) sequences of 18-24
bp, with a Tm near 60°C that produced an amplicon 100 to 250 bp, 2) acceptable
3’ stability, and 3) minimal nucleotide repeats and single nucleotide repetitive
runs. Two potential forward and reverse primers were identified for the upstream
probes (Table 3). The four primers designed for the upstream amplicon were
tested in all possible configurations and analyzed by gel electrophoresis for
amplification (Fig. 7). Three potential forward and four potential reverse primers
were identified for the downstream probes. The five primers designed for the
downstream amplicon were tested in all possible configurations and analyzed on
gel electrophoresis for amplification (data not shown). The primers 15S557(19)F
and 16S786(23)R had the highest PCR product yield and were selected for
amplification of upstream amplicon. The primers 16S945(20)F and
16S1222(20)R had the highest PCR product yield and were selected for
amplification of downstream amplicon.
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Upstream Primer
16S557(19)F *
16S560(18)F
16S786(18)R
16S786(23)R *

Primer Sequence (5’-3’)
GGAATTACTGGGCGTAAAG
TTTATTGGGCGTAAAGCG
CTACCAGGGTATCTAATC
GTGGACTACCAGGGTATCTAATC

Downstream Primer
16S945(20)F *
16S946(18)F
16S968(18)F
16S1191(18)R
16S1209(19)R
16S1210(18)R
16S1222(20)R *

Primer Sequence (5’-3’)
GAGCATGTGGTTTAATTCGA
AGCATGTGGTTTAATTCG
AACGCGAAGAACCTTACC
GGCATGATGATTTGACGT
TGTAGCCCAGGTCATAAGG
TGTAGCCCAGGTCATAAG
CATTGTAGCACGTGTGTAGC

Table 3. Primers tested for the amplification efficiency for Molecular
Gram-stain assay. The primers are listed according to their upstream and
downstream targets. The primers in bold and marked with an astericks
were selected for use in the Molecular Gram-stain assay.
!
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Figure 7. An electrophoresis gel analysis of different primer pair
efficiencies. Each primer pair set was used to amplify E. coli genomic
DNA and the PCR products were electrophoresised through a 1% agarose
gel, stained with ethidium bromide, and photographed. Lanes: 1) primers
16S560(18)F and 16S786(18)R, 2) primers 16S560(18)F and
16S786(23)R, 3) primers 16S557(19)F and 16S786(18)R, 4) primers
16S557(19)F and 16S786(23)R.
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Primer and probe optimization
Compatible primer pairs were tested in conventional PCR analysis using Qiagen
QuantiFast SYBR Green PCR Kit (QIAGEN) master mix and the amount and specificity
of amplification was compared by electrophoresis through agarose. The primer pairs
showing the highest product yields were tested subsequently by qPCR. Both of these
analyzes were performed with the same standard template DNA: (S. aureus DNA [2.85
ng/ml], E. faecalis DNA [2.81 ng/ml], P. aeruginosa DNA [4.96 ng/ml] and E. coli DNA
[5.59 ng/ml]). First, the primers were tested to determine that they universally anneal to
bacterial species and amplified the target regions efficiently. Subsequently, the primer
pair 15S557(19)F/16S786(23)R was used to test the upstream probe set and primer
pair R16S945(20)F/16S1222(20)R was used to test the downstream probe set. For all
of these tests the standard template DNA solutions were prepared by making four 1:10
dilutions. For example, the S. aureus template DNA was used at 2.8 ng/ml, 0.28 ng/ml,
0.028 ng/ml, and 0.0028 ng/ml. Each assay was then tested for efficiency after EMA
pretreatment.

SYBR Green qPCR analysis of primers
The primers that produced the best yields using standard PCR with
electrophoresis analysis were tested for amplification efficiency using SYBR
Green qPCR analysis. The Ct values were plotted against the log dilutions of
DNA concentrations to create standard curves. Melting curve analysis was also
performed to test for the amplification of non-specific products. The slope of the
trend line that is generated from the standard curve can determine the
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amplification efficiency. A trend line slope of 3.33 is indicative of 100% efficiency
in the amplification cycles, which represents a 2-fold increase in detection
between Ct values. Trend lines with slopes less than 3.33 are indicative of
greater than 100% efficiency and trend lines with slopes greater than 3.33 are
indicative of lower than 100% efficiency.
For the upstream primer set, 15S557(19)F and 16S786(23)R, a standard
curve slope of 2.3 was produced on E. faecalis, 2.7 for S. aureus, 2.8 for P.
aeruginosa, and 2.9 for E. coli (Fig. 8 A and B). Each reaction produced trend
lines indicative of a greater than 100% efficiency, which is most likely the result of
high primer concentration and slight amplification of the bacterial DNA present in
the qPCR master mix and reagents. This leads to a slight plateau at the higher
Ct values. The melting curve analysis for the upstream primers detected no
amplification of non-specific products.
The downstream primer set, 16S945(20)F and 16S1222(20)R, produced
standard curve slopes of 3.0 for E. faecalis, 3.2 for S. aureus, 2.8 for P.
aeruginosa and for E. coli (Fig. 9 A and B). Trend lines indicative of amplification
efficiencies of greater than 100% were again produced and were likely to be a
result of primer concentration and contaminant amplification. Melting curve
analysis showed that there were no non-specific products amplified in the
reaction.
As all four of these primers resulted in high amplification efficiency and no
non-specific amplification, they were all chosen for assay development. No
!
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Figure 8. Standard curve analysis of upstream primers 16S557(19)F and
16S786(23)R. (A) Primers 16S557(19)F and 16S786(23)R amplifying Grampositive species S. aureus and E. faecalis. (B) Primers 16S557(19)F and
16S786(23)R amplifying Gram-negative species E. coli and P. aeruginosa.
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Figure 9. Standard curve analysis of upstream primers 16S945(20)F and
16S1222(20)R. (A) Primers 16S945(20)F and 16S1222(20)R amplifying Grampositive species S. aureus and E. faecalis. (B) Primers 16S945(20)F and
16S1222(20)R amplifying Gram-negative species E. coli and P. aeruginosa.
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further SYBR Green optimization was performed. Additional optimization was
required for the qPCR assay with the Taqman probes.

Testing probes on Gram-positive and Gram-negative genomic DNA
The specificity and efficiency of the upstream and downstream primer and
probe sets were determined using a range of four orders of magnitude of
genomic DNA equivalent to 102 to 105 cells/ml of S. aureus, E. faecalis, P.
aeruginosa and E. coli DNA as template. The upstream universal probe
P16S683U was tested using primers 16S557(19)F and 16S786(23)R. Probe
P16S683U detected all bacterial DNA tested with amplification efficiencies of
approximately 75% (Fig. 10 A, B). The Gram-positive upstream probe P16S706P
was tested using the same primers (16S557(19)F and 16S786(23)R). Probe
P16S706P detected only Gram-positive DNA with amplification efficiencies of
approximately 86% (Fig. 11 A, B).
The downstream Gram-positive probe P16S1194P was tested using
primers 16S945(20)F and 16S1222(20)R. Probe P16S1194P amplified the only
Gram-positive bacterial DNA with approximately 89% efficiency (Fig. 12 A, B).
The downstream Gram-negative probe P16S1194N was testing using the same
primers (16S945(20)F and 16S1222(20)R). Probe P16S1194N amplified only the
Gram-negative bacterial DNA with approximately 70% efficiency (Fig. 13 A, B).
The downstream probes, P16S1194P and P16S1194N, share the same
probe target region, which contains two nucleotide mismatches. This could result
in competition for the binding sites. An analysis of competitive binding was
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Figure 10. Fluorescent detection and standard curve plots for the upstream
Probe 16S683U. A) Amplification of probe 16S683U analyzing E. coli, P.
aeruginosa, S. aureus and E. faecalis DNA. B) Standard curve for probe
16S683U analyzing E. coli, P. aeruginosa, S. aureus and E. faecalis DNA.
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Figure 11. Fluorescent detection and standard curve plots for the upstream
probe P16S706P. A) Amplification of probe P16S706P analyzing E. coli, P.
aeruginosa, S. aureus and E. faecalis DNA. B) Standard curve for probe
P16S706P analyzing E. coli, P. aeruginosa, S. aureus and E. faecalis DNA.
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Figure 12. Fluorescent detection and standard curve plots for the
downstream probe P16S1194P. A) Amplification of probe P16S1194P
analyzing E. coli, P. aeruginosa, S. aureus and E. faecalis DNA. B) Standard
curve for probe P16S1194N analyzing E. coli, P. aeruginosa, S. aureus and E.
faecalis DNA.
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Figure 13. Fluorescent detection and standard curve plots for the
downstream probe P16S1194N. A) Amplification of probe P16S1194N
analyzing E. coli, P. aeruginosa, S. aureus and E. faecalis DNA. B) Standard
curve for probe P16S1194N analyzing E. coli, P. aeruginosa, S. aureus and E.
faecalis DNA.
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performed using probes P16S1194P and P16S1194N in singleplex and duplex
reactions. The downstream Gram-positive probe P16S1194P was tested by
using as template a four order of magnitude range of genomic DNA equivalent to
102 to 105 cells/ml from E. faecalis. There was no significant difference between
the specificity and efficiency in the singleplex reactions and the duplex reactions
in which it was coupled with probe P16S1194N (Fig. 14A). In converse, the
downstream, Gram-negative probe P16S1194N was tested by using as template
a four order of magnitude range of genomic DNA equivalent to 102 to 105 cells/ml
from E. coli. There was no significant difference in the specificity and efficiency
between the singleplex reactions and the duplexed reactions in which it was
coupled with probe P16S1194P (Fig. 14B).
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Figure 14. Analysis of competitive binding for downstream probes. A) Probe
P16S1194P is analyzed using E. faecalis.DNA as a template in singleplex
reactions. In the duplex reactions the P16S1194N probe is included. E. coli and
P. aeruginosa templates are added in two of the duplex reactions as negative
controls. B) Probe P16S1194N is analyzed using E. coli DNA as a template in
singleplex reactions. In the duplex reactions the P16S1194P probe is included.
S. aureus and E. faecalis DNA are added in two of the in duplex reactions as
negative controls.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

!

47!

+
EMA decontamination treatment
Bacterial DNA is commonly found as a contaminant in commercially
available PCR and qPCR solutions (53) and can be detected with primers and
probes specific for the 16S rRNA genes. To eliminate this background
contamination from the reagents, I first treated them with ethidium monoazide
(EMA), which covalently intercalates into the double-stranded DNA and
eliminates it from further denaturation, so that it cannot serve as a template in
PCR reactions (54, 55). As a result, the optimization of the assay included
testing pretreatment of the reagents with various concentrations of EMA (4 µM to
15 µM). At a concentration of 9 µM no inhibition of the qPCR reaction was
observed and the background amplification was removed (Fig. 15). In this test
reaction S. aureus genomic DNA was used at concentrations corresponding to
103 ,104 and 105 chromosomal equivalents. Samples were either treated or not
treated with EMA (Fig, 15). Elimination of the high Ct value background
amplification was observed with a 9 µM EMA pretreatment.
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Figure 15. Effects of EMA treatment on qPCR reaction. Amplification plots
are shown of three log dilutions of S. aureus DNA with and without EMA (9 µM)
pretreatment of qPCR mastermix. Samples with EMA pretreatment are shown in
blue. Samples without EMA pretreatment are shown in green. The reagents
alone without EMA treatment is shown in orange. The reagents alone with EMA
treatment is shown in red.
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Synthesis and testing of phosphorothioate blocking oligonucleotides
There is concern that in a multiplex reaction in which all four probes were present
there would be interference of the amplification of the desired products by amplification
from outlying primers that occur because of the close proximity of the primer target sites
(Fig. 16). To resolve this issue I developed phosphorothioate blocking oligonucleotides
to prevent the generation of large PCR amplicons that arise from the amplification of
products from outlying primers that occur in multiplex PCR reactions with targets in
close proximity (Fig. 16).
Oligonucleotides in which a sulfur atom replaces one of the non-bridging
oxygen’s on the phosphate linkage are termed phosphorothioates (Fig. 17). This
modification is known to provide greater resistance to enzymatic hydrolysis including to
the exonucleolytic activity of DNA polymerase (56, 57). Phosphorothioates have been
used in various applications including mutagenesis, antisense gene regulation, and
single nucleotide polymorphism (SNP) genotype analysis (58-60).
I designed a functional phosphorothioate-containing oligonucleotide that anneals
to the template DNA between the reverse primer of an upstream target (UpRp) and the
forward primer of the downstream product (DnFp). This ‘blocking oligo’ prevents the
amplification of the entire undesired amplicon (UpFp to DnRp) (Fig. 18). Specifically, I
designed a 23-mer ‘blocking oligo’ that contains five phosphorothioate-modified linkages
at the 5’ end that are directly followed by a nine-nucleotide region enriched in guanine
and cytosine nucleotides, termed a ‘GC clamp’, and includes four adenines at the 3’

!

50!

A."

B."

UpFp"

DnFp"
UpRp"

DnRp"

UpFp"

DnFp"
UpRp"

DnRp"

!"Upstream"Forward"Primer"(UpFp)"
!"Upstream"Reverse"Primer"(UpRp)"
!"Blocking"Oligo"
!"Genomic"DNA"

!"Downstream"Forward"Primer"(DnFp)"
!"Downstream"Reverse"Primer"(DnRp)"
!"Target"AmpliﬁcaBon"
!"Flanking"AmpliﬁcaBon"

!

C."
Upstream)F)

+)

,)

+)

+)

Figure 16. SchematicUpstream)R)
diagram of
the
use
of phosphorothioate
+)
,)
,)
,)
blocking oligonucleotides.
blocking
Downstream)F) The ,)phosphorothioate
+)
,)
,)
Downstream)R)
,)
+)
+)
+)
oligonucleotides prevent
the generation
of large
PCR amplicons that arise
Oligo)w/o)Pt)bases)
,)
,)
+)
,)
from the amplificationOligo)Pt)bases)
of products,) from
outlying
primers that occur in
,)
,)
+)
multiplex PCR reactions with primer targets in close proximity. (A) Two
PCR targets in close proximity facilitate the generation of a large PCR
amplicon by amplification initiating from the outlying primers (UpFp and
Flanking"ampliﬁcaBon"
DnRp). (B) The phosphorothioate blocking oligonucleotide
anneals to the
template downstream of the upstream forward primer
and
terminates
Target"ampliﬁcaBon"
extension.
Primer"Dimers"

!
!
!
!
!
!
!
!
!
!
!
!
!

51!

!
!

!

!

A.#

B.#
O#

CH2#

O#

Base#

CH2#

O#

O#

O#

O#

O# P# O'H+#
O#

Base#

S# P# O'H+#

CH2#

O#

Base#

CH2#

O#

Base#
O#

O#

O#
!

Figure 17. 5’ to 3’ Phosphodiester linkage and 5’ to 3’
phosphorothioate linkage. (A) A phosphodiester linkage contains two
non-bridging oxygens (one is shown in red). (B) A phosphorothioate
linkage contains a non-bridging oxygen and a non-bridging sulfur shown in
red.
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Figure 18. A model of the phosphorothioate barrier to PCR
amplification. (A) The phosphorothioate blocking oligonucleotide anneals
to the template downstream of the upstream forward primer. The DNA
polymerase extends from the upstream forward primer toward the blocking
oligo. (B) and (C) The polymerase encounters the blocking oligo and is
unable to hydrolyze the phosphorothioate-modified nucleotides. The
extension is terminated and the polymerase detaches from the DNA. (D) If
the blocking oligo lacking the phosphorothioate modifications anneals to
the template, the 5’ to 3’ exonuclease activity of polymerase removes the
nucleotides and extension is completed. Note: The phosphorothioate
blocking oligo can also be designed to anneal downstream of the reverse
primer.
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end. The phosphorothioate modifications block the 5’ to 3’ exonuclease activity of the
DNA polymerase and terminate extension. The ‘GC clamp’ ensures specific and strong
annealing. The four 3’ adenines are designed to be mismatches and prevent possible
extension from the blocking oligonucleotide. These specific design elements will be
different for each target, but will always include four to five phosphorothioate-modified
linkages at the 5’ end, followed by a strong ‘GC clamp’, and have four to five
mismatches at the 3’ end.
I have demonstrated that phosphorothioates can be used as a barrier to PCR
amplification. Experimental results show that an oligonucleotide containing all of our
blocking oligo parameters except phosphorothioate modifications is not capable of
blocking flanking amplification; however, this same nucleotide sequence with the
phosphorothioate modifications is able to block flanking amplification (Fig. 19). It is
anticipated that these ‘blocking oligos’ will have important applications.
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Figure 19. The use of phosphorothioate blocking oligonucleotides to
prevent the generation of large PCR amplicons. The large PCR amplicons
arise from the amplification of products from outlying primers that occur in
multiplex PCR reactions with targets in close proximity. (A) An agarose gel
shows the presence of the large flanking amplicon resulting from amplification
from the outlying primers in the reaction in which the blocking oligonucleotide
lacked the phosphorothioate linkage modifications (lane 3) and elimination of the
large amplicon in the reaction with the phosphorothioate blocking oligo (lane 4).
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Testing S. aureus viability with EMA and PMA exposure
Initially when performing the artificial blood contamination experiments
(see below) I found that S. aureus DNA was detected at one order of magnitude
below the concentration of cells added to the blood samples. After reviewing the
literature and performing some experiments, I hypothesized that the EMA-treated
PBS used for the washing and dilution steps was toxic to the S. aureus cells (61,
62). To test this idea, I performed an experiment in which I exposed S. aureus
cells to EMA-treated PBS for 10 and 30 min and to with non-EMA treated PBS as
a control. I found that after a 10-min incubation with EMA-PBS there was
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approximately a one-log loss in cell viability when compared to the non-EMA
exposed cells. After exposure to EMA-PBS for 30 min no viable cells were
recovered. I performed the same experiments in which EMA was replaced with
PMA and found that there was no significant difference between the PMA-treated
PBS and the non-treated PBS. Therefore, I replaced the EMA with PMA only in
the reagent pretreatment protocol for the PBS solution used to suspend and
dilute the live cells before DNA extraction. These samples served as controls for
the experiments that tested the efficiency of extracting DNA from blood samples.

Testing the qPCR assay in artificial blood samples
Detection of S. aureus DNA in Blood and PBS
To evaluate the sensitivity and reproducibility of the MGS assay, artificial
blood samples were prepared containing each of four laboratory strains of
representative Gram-positive (S. aureus and E. faecalis) and Gram-negative (E.
coli and P. aeruginosa) bacteria at concentrations ranging from 101 to 105 cell/ml.
As an additional control, similar samples were prepared in PBS. Yeast genomic
DNA (200 ng) was added as carrier DNA to the PBS samples. Each of these
eight samples was treated using the standard MGS assay protocol. The DNA
was extracted, quantified, and a qPCR reaction was performed and analyzed.
The efficiency of the whole protocol from DNA extraction through analysis was
compared to the input cell concentration that was based on colony counts.
The S. aureus DNA detected in the blood ranged from 34 to 83 percent of
the number of input cells from which it was extracted (2.3 x 102 to 2.3 x 105
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cells/ml). The limit of detection for S. aureus cells was estimated at 100 cells/ml,
as the DNA was not generally detected in blood at input cell concentrations less
than 102 cells/ml. Interestingly, the DNA detected from the cells resuspended in
PBS had a poor correlation with the input cell concentrations. The S. aureus
DNA detected in the PBS ranged from 0 to 20 percent of the numbers of input
cells from which it was extracted. This poor recovery was observed with all of
the different bacterial cells suspended in PBS (see above). Furthermore, the
limit of detection for the PBS samples was approximately 1000 cells/ml. As
expected the universal and Gram-positive probes amplified all of the S. aureus
DNA samples and no signal was detected from the Gram-negative probe (Table
4).
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CFU+per+ml+
added+to+
blood+
(determined+
by+plate+
count)+

Blood+
Upstream++

Downstream+

Universal+

Gram+++

Gram+++

Gram+%+

Average+value+

%+Detection+

2.3+x+105+

103840+(45%)+

64620+(28%)+

68260+(29%)+

%+

7.8+x+104+

34+

2.3+x+10 +

13790+(60%)+

13870+(60%)+

15720+(68%)+

%+

1.4+x+10 +

61+

2.3+x+103+

1290+(56%)+

2260+(98%)+

2160+(94%)+

%+

1.9+x+103+

83+

2.3+x+102+

150+(65%)+

80+(35%)+

50+(22%)+

%+

9.3+x+101+

40+

2.3+x+101+

60+(260%)+

%+

%+

%+

%+

%+

+

+

+

+

+

+

+

CFU+per+ml+
added+to+
blood+
(determined+
by+plate+
count)+

PBS+

+

+

+

+

Universal+

Gram+++

Gram+++

Gram+%+

Average+value+

%+Detection+

2.3+x+105+

6180+(3%)+

4370+(2%)+

18230+(8%)+

%+

9.5+x103+

4+

2.3+x+104+

570+(2%)+

340+(1%)+

3730+(16%)+

%+

4.6+x+103+

20+

2.3+x+103+

20+(1%)+

%+

260+(11%)+

%+

%+

%+

2.3+x+102+

%+

%+

%+

%+

%+

%+

2.3+x+101+

%+

%+

%+

%+

%+

%+

4

Upstream+

Downstream+

4

Table 4. Detection of S. aureus DNA from inoculated blood and PBS
samples.

+
Detection of E. faecalis DNA in Blood and PBS
The E. faecalis DNA detected in the blood ranged from 34 to 81 percent of
the number of input cells from which it was extracted. The limit of detection of E.
faecalis cells, similar to S. aureus, was estimated at 100 cells/ml, as no DNA was
detected in the blood at concentrations less than 102 cells/ml. In this case, the
DNA extracted from cells resuspended in PBS has more correlation with the
number of input cells. The E. faecalis DNA detected in PBS ranged from 60 to
!
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132 percent of the numbers of input cells. The limit of detection of E. faecalis
cells in PBS was again estimated at 100 cells/ml. The probes amplified as
expected for Gram-positive samples in all of the E. faecalis assays (Table 5)
!
!
!
!
!
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CFU+per+ml+
added+to+
blood+
(determined+
by+plate+
count)+

Blood+
Upstream++

Downstream+

Universal+

Gram+++

Gram+++

Gram+%+

Average+value+

%+Detection+

3.6+x+105+

208080+(57%)+

113270+
(31%)+

50940+(14%)+

%+

1.2+x+105+

34+

3.6+x+104+

19510+(54%)+

17350+(48%)+

30880+(85%)+

%+

2.2+x+104+

63+

3.6+x+103+

1630+(45%)+

2110+(58%)+

2930+(81%)+

%+

2.2+x+103+

62+

3.6+x+10 +

420+(116%)+

170+(47%)+

280+(77%)+

%+

2.9+x+10 +

81+

3.6+x+101+

%+

%+

%+

%+

%+

%+

+

+

+

+

+

+

+

CFU+per+ml+
added+to+
blood+
(determined+
by+plate+
count)+

PBS+

+

+

+

+

2

Upstream+

Downstream+

2

Universal+

Gram+++

Gram+++

Gram+%+

+

+

3.6+x+105+

384050+
(106%)+

196720+
(54%)+

64650+(17%)+

%+

2.1+x105+

60+

3.6+x+104+

41700+(115%)+

29920+(83%)+

40480+
(112%)+

%+

3.7+x+104+

103+

3.6+x+103+

4510+(125%)+

4710+(130%)+

5090+(141%)+

%+

4.7+x+103+

132+

3.6+x+102+

350+(97%)+

420+(116%)+

190+(52%)+

%+

3.2+x+102+

89+

3.6+x+101+

40+(111%)+

%+

%+

%+

%+

%+

Table 5. Detection of E. faecalis DNA from inoculated blood and PBS
samples.
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+
Detection of E. coli DNA in Blood and PBS
The E. coli DNA detected in the blood ranged from 66 to 169 percent of
the numbers of input cells from which it was extracted. The limit of detection of
E. coli cells in blood was approximately 10 cells/ml with the upstream universal
probe, as DNA was detected at all the DNA concentrations. The limit of
detection of was approximately 100 cells/ml with the downstream Gram-negative
probe, as DNA was not generally detected in the blood at cell concentrations less
than 102 cells/ml. The E. coli DNA detected in PBS ranged from 70 to 198
percent of the number of input cells. The limit of detection of E. coli cells in PBS
was approximately 100 cells/ml, as DNA was not detected in PBS at cell
concentrations less than the 102 cells/ml. As expected, the universal and Gramnegative probe amplified all the DNA and no signal was detected using the
Gram-positive probes (Table 6).
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CFU+per+ml+
added+to+
blood+
(determined+
by+plate+
count)+

Blood+
Upstream++

Downstream+

Universal+

Gram+++

Gram+++

Gram+%+

Average+value+

%+Detection+

3.6+x+105+

281360+(78%)+

%+

%+

194680+(54%)+

2.3+x+105+

66+

3.6+x+104+

27890+(77%)+

%+

%+

62370+(173%)+

4.5+x+104+

125+

3.6+x+103+

2590+(71%)+

%+

%+

9610+(266%)+

6.1+x+103+

169+

3.6+x+102+

410+(113%)+

%+

%+

402+(111%)+

4+x+102+

112+

3.6+x+101+

180+(692%)+

%+

%+

%+

%+

%+

+

+

+

+

+

+

+

CFU+per+ml+
added+to+
blood+
(determined+
by+plate+
count)+

PBS+

+

+

Downstream+

+

+

Universal+

Gram+++

Gram+++

Gram+%+

Average+value+

%+Detection+

3.6+x+105+

209440+(81%)+

%+

%+

155770+(60%)+

1.8+x105+

70+

3.6+x+104+

9740+(38%)+

%+

%+

29240+(113%)+

3.8+x+104+

75+

3.6+x+103+

1020+(40%)+

%+

%+

6910+(265%)+

3.9+x+103+

152+

3.6+x+102+

170+(65%)+

%+

%+

860+(330%)+

5.1+x+102+

198+

3.6+x+101+

%+

%+

%+

%+

%+

%+

Upstream+

Table 6. Detection of E. coli DNA from inoculated blood and PBS samples.

Detection of P. aeruginosa DNA in Blood and PBS
The P. aeruginosa DNA detected in the blood ranged from 84 to 225
percent of the number of input cells. The limit of detection of P. aeruginosa cells
was approximately 10 cells/ml with the upstream universal probe, as DNA was
detected in samples at all DNA concentrations. The limit of detection of P.
!
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aeruginosa cells was approximately 100 cells/ml with the downstream Gramnegative probe, as DNA was not generally detected in the samples at cell
concentrations less than 102 cells/ml. The P. aeruginosa DNA detected in PBS
ranged from 74 to 140 percent of the number of input cells. The limit of detection
for the PBS was approximately 10 cells/ml. As expected, the universal and
Gram-negative probe amplified all DNA and no signal was detected from the
Gram-positive probes (Table 7).
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+
CFU+per+ml+
added+to+
blood+
(determined+
by+plate+
count)+

Blood+
Upstream++

Downstream+

Universal+

Gram+++

Gram+++

Gram+%+

Average+value+

%+Detection+

4.6+x+105+

568840+(123%)+

%+

%+

212810+(46%)+

3.9x+105+

84+

4.6+x+104+

77370+(168%)+

%+

%+

23630+(51%)+

5+x+104+

109+

4.6+x+103+

8430+(183%)+

%+

%+

7890+(171%)+

8.1+x+103+

177+

4.6+x+102+

1070+(232%)+

%+

%+

1016+(220%)+

1+x+103+

225+

4.6+x+101+

60+(130%)+

%+

%+

%+

%+

%+

+

+

+

+

+

+

+

CFU+per+ml+
added+to+
blood+
(determined+
by+plate+
count)+

PBS+

+

+

+

+

Universal+

Gram+++

Gram+++

Gram+%+

Average+value+

%+Detection+

4.6+x+105+

413170+(89%)+

%+

%+

297490+(114%)+

3.5+x105+

77+

4.6+x+10 +

44680+(97%)+

%+

%+

84550+(183%)+

6.4+x+10 +

140+

4.6+x+103+

4720+(102%)+

%+

%+

2116+(46%)+

3.4+x+103+

74+

4.6+x+102+

820+(178%)+

%+

%+

264+(57%)+

5.4+x+102+

117+

4.6+x+101+

14+(30%)+

%+

%+

70+(152%)+

4.2+x+101+

91+

4

Upstream+

Downstream+

4

Table 7. Detection of P. aeruginosa DNA from inoculated blood and PBS
samples.
!
!
Analysis of clinical samples
Eighteen clinical samples were analyzed using the MGS assay and
compared to results obtained by the Memorial Hermann Hospital Clinical
Microbiology Laboratory. The Clinical Microbiology Laboratory, using culture and
Gram-staining classified two of the 18 clinical samples (11%) as positive and 16
(89%) as negative (Table 8). Of the two positive samples, both were identified as
Gram-negative bacteria by both the Clinical Microbiology Laboratory and the
!
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!

Upstream!
Universal!
Gram!+!
Sample! Patient!! P16S683U! P16S706P!
Cells/ml!
Cells/ml!
S5!
Pt5!
50*!
0!
S15!
Pt10!
210!
0!
!
!
!
!
S7!
Pt3!
0!
0!
S3!
Pt3!
0!
0!
S2!
Pt2!
0!
0!
S4!
Pt4!
0!
0!
S8!
Pt5!
30*!
0!
S16!
Pt11!
0!
0!
!
!
!
!
S10!
Pt3!
0!
0!
S13!
Pt3!
80*!
0!
S6!
Pt6!
7490!
0!
S9!
Pt7!
50*!
0!
S11!
Pt8!
610!
0!
S12!
Pt4!
0!
0!
S14!
Pt9!
990!
0!
S17!
Pt10!
1070!
0!
S18!
Pt12!
1910!
0!
S19!
Pt13!
320!
0!
!
!
!
!

Downstream!
!
Gram!+!
Gram!;!
P16S1194P! P16S1194N!
Blood!Culture!
Cells/ml!
Cells/ml!
Result!
0!
360!
+!(Gram;negative)a!
0!
50*!
+(Gram;negative)b!
!
!
!
0!
0!
%+/!Expired!
0!
90*!
%+/!Expired!
0!
0!
%!
0!
0!
%!
0!
0!
%!
0!
0!
%!
!
!
!
0!
7050!
%+/!Expired!
0!
1230!
%+/!Expired!
0!
827550!
%!
0!
4850!
%!
0!
10140!
%!
0!
490!
%!
0!
6900!
%!
0!
3850!
%!
0!
0!
%!
0!
150!
%+/!Expired!
!
!
!

Table 8. Analysis of clinical blood sample pellets with the Molecular Gramstain assay. Samples highlighted in yellow are positive blood samples with
100% congruence with the Molecular Gram-stain assay results. Samples
highlighted in green are negative blood samples. Data highlighted in orange are
negative blood samples that have 62% congruence with the Molecular Gramstain assay results. a 22 hr to blood culture results. b 18 hr to blood culture
results. An asterisk represents samples for which the values are below limit of
detection. The values (cell/ml) are calculated based on E. coli standards for the
samples that were detected by the universal and Gram-negative probes. S =
sample, Pt = Patient.
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MGS assay. This represents 100% congruence between the samples that were
measured as positive by the ‘gold standard’ of blood culture and Gram-stain.
The Clinical Microbiology Laboratory after further analysis determined that these
samples were E. coli (sample #5) andSerratia marcescens (sample #15).
Of the 16 culture-negative samples, six were also determined by the MGS
assay to lack amplifiable bacterial DNA above the threshold equivalent to 100
cells/ml. This represents 37% congruence between the culture-negative samples
and the MGS assay negative samples. Ten of the 16 culture-negative samples
resulted in amplification of bacterial DNA above the 100-cell/ml threshold. This
represents 62% non-congruence between the culture-negative samples and the
MGS assay.
The average time to determination (TTD) of a positive blood culture result
was 16.8 hr for the clinical laboratory (Table 8). The TTD for the MGS assay was
estimated to be 4.5 hr by calculating the times required for sample processing,
DNA extraction, and qPCR analysis.
I hypothesized that live and dead bacteria in the clinical blood samples
could be differentiated by detection of DNA in the samples after centrifugation;
the DNA from live cells would be associated with the pellet and the DNA of dead
(lysed) cells would be in the plasma (supernatant). To test this hypothesis, I
centrifuged all of the blood samples after collection and stored the pellet and
supernatant separately at until analysis. The plasma DNA was extracted for
samples #8 though #19 and used as template for the MGS assay (Table 9). The
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!
Sample! Patient!! P16S683U!
Cells/ml!
!
!
!
S8!
Pt5!
30*!

P16S706P!
Cells/ml!
!
0!

P16S1194N!
Cells/ml!
!
0!

P16S1194P!
Cells/ml!
!
0!

Blood!Culture!
Result!
!
%!

S8P!

Pt5!

0!

0!

10*!

20*!

%!

S16!
S16P!
S12!
S12P!
S17!
S17P!
S19!
S19P!
S11!
S11P!
S13!
S13P!
S9!
S9P!
S14!
S14P!

Pt11!
Pt11!
Pt4!
Pt4!
Pt10!
Pt10!
Pt13!
Pt13!
Pt8!
Pt8!
Pt3!
Pt3!
Pt7!
Pt7!
Pt9!
Pt9!

0!
0!
0!
0!
1070!
0!
320!
0!
610!
0!
80*!
0!
50*!
20*!
990!
0!

0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!

0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!
0!

%!
%!
%!
%!
%!
%!
%!
%!
%!
%!
%!
%!
%!
%!
%!
!

S10!
S10P!

Pt3!
Pt3!

0!
0!

0!
0!

0!
0!

%!
%!

S18!
S18P!
S15!
S15P!
!

Pt12!
Pt12!
Pt10!
Pt10!
!

1910!
510!(27%)!
210!
0!
!

0!
0!
0!
0!
!

0!
0!
490!
0!
3850!
0!
150!
0!
10140!
90*!
1230!
17*!
4850!
880!(18%)!
6900!
3830!
(55%)!
7050!
6450!
(91%)!
0!
0!
50!(0.12)*!
39190!
!

0!
0!
0!
0!
!

%!
%!
+(Gram;negative)!
%+
!

Table 9. Analysis of clinical blood sample pellet compared with plasma.
Samples highlighted in yellow are classified as positive blood samples and the
plasma amplification value is higher than the pellet. Samples that are not
highlighted are amplification-negative. Samples highlighted in blue are plasma
amplification-negative and pellet positive. The samples highlighted in green are
amplification-positive for both plasma and pellet. The samples highlighted in
orange are universal probe positives. An asterisk represents samples for which
the values are below limit of detection. S = sample, P = plasma, Pt = patient.
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the plasma was not preserved for samples #2 through #7. For two of these
samples (#8 and #16) there was no amplification above background detected for
the plasma or the pelleted samples. For five of the samples (#11, #12, #13, #17,
and #19) the plasma values were negligible, whereas the pellet samples were
above background. For three of these samples (#9, #10, #14) the plasma values
were above background and ranged from 18-91% of the pelleted value, but were
always less than the pellet levels. For all of the plasma samples, except #18, the
values for the universal primer were negligible. However, #18 was only amplified
by the universal primer for both the plasma and pellet samples and the plasma
amplification was 20% of that of the pellet. For only one sample (#15) that was
positive by both culture and Gram-strain and MGS assay, was the value of the
DNA in the plasma greater than the pellet. In this case the amplification in the
plasma indicated that there was greater than 100 times more DNA in the plasma
than in the pellet. This patient was released from the hospital, so presumably the
antimicrobial treatment was effective and caused the DNA from many lysed cells
or extruded DNA to be present in the plasma.
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DISCUSSION

Sepsis is a severe and lethal health problem that is a growing concern
with respect to patient outcomes and financial considerations. The current
clinical ‘gold standard’ technique of blood culture and Gram-stain analysis used
to diagnose sepsis has many shortcomings. Many molecular methods for the
identification of pathogens associated with sepsis are being developed. These
methods generally focus on rapid and accurate pathogen identification and
include techniques such as PCR, microarrays, mass spectroscopy, NMR, and
microscopy.
I have developed a novel quantitative real-time PCR assay to detect and
classify the Gram-status of essentially all bacterial pathogens that is based on 33
bacterial pathogens commonly recovered from sepsis patients in the Memorial
Hermann Hospital Surgical Trauma Intensive Care Unit. The MGS assay was
designed to include internal checks and balances to provide an accurate
detection and differentiation method. The assay utilizes a dual amplicon
approach with two probes per amplicon to detect essentially all bacterial DNA by
hybridization to a universally conserved region and to differentiate Gram-positive
and Gram-negative bacterial DNA by hybridization to regions specific to these
two types of bacteria.
The MGS assay was initially optimized using purified bacterial DNA.
Subsequently, the entire protocol from DNA extraction through analysis was
tested and optimized in samples in which each one of the four representative
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bacterial species were added to previously uninfected human blood samples and
PBS independently in a range of five orders of magnitude concentrations (101 to
105). Finally, 18 clinical blood samples from patients suspected to have sepsis
were analyzed by the MGS assay and the Memorial Hermann Hospital Clinical
Microbiology Laboratory and the results were compared.
I have determined that the assay is capable of quantitatively measuring
the concentration of bacterial DNA of S. aureus, E. faecalis, P. aeruginosa and E.
coli extracted from blood and PBS with amplification efficiencies from 70 to 90%.
The universal probe P16S683U detected DNA of all four bacterial species tested
and was determined by in silico analysis to identify many other genera and
species. The two Gram-positive probes, P16S706P and P16S1194P, detected
both of the Gram-positive species without detecting the two Gram-negative
species. In addition, in silico analysis determined that the probes could detect
many other Gram-positive genera and species, but not Gram-negative species.
The Gram-negative probe P16S1194N detected both of the Gram-negative
species without detecting the two Gram-positive species and in silico analysis
determined that it detected many other Gram-negative genera and species, but
not Gram-positive species.
The MGS assay analysis of the 18 clinical blood samples was compared
to results obtained by the Memorial Hermann Hospital Clinical Microbiology
Laboratory. There was 100% congruence between the two positive blood culture
results and the MGS assay results. In both cases, the pathogens identified were
Gram-negative bacteria. There was 37% congruence between the 16 culture-
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negative samples and the MGS assay results, as six of these samples were also
detected as amplification negative by the MGS assay or the values detected
were below the 100-cell/ml threshold limit of detection. There was 62% noncongruence between the culture-negative samples and the MGS assay results,
as ten of the 16 culture-negative samples were amplification positive by the MGS
assay.
One of the advantages of the MGS method over other molecular detection
methods is that this method can ‘rule out’ infection as the cause of patient’s
symptoms. A ‘rule out’ is possible due to the inclusion in the assay of the
universal probe that will bind to essentially any bacterial DNA in the sample. All
other assays developed to date are a ‘rule in’ type, in which the method is used
to determine if the sample contains a pathogen included in the list of organisms
that can be detected by the method. As a result, if a bacterium not within the
group is the causative organism it will not be detected and thus, cannot be ruled
out. This leaves physicians to depend on the blood culture results. However, it
is clear that blood culture is not a definitive assay, as many bacteria will not grow
well enough to reach the approximately 105-cell/ml requirement for detection.
Furthermore, the high number (62%) of samples here that were negative by
culture, but resulted in a positive amplification supports this concept.
The MGS assay had a faster TTD, which was estimated as 4.5 hr from
sample arrival in the laboratory through analysis. The positive blood culture and
Gram-stain analysis required an average of 16.8 hr until the information was
transmitted to the physician. It is important to note that when the blood culture
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analysis was negative the ‘TTD’ was 5-7 days. Although blood culturing is the
current ‘gold standard’ in pathogen detection in blood samples, it appears that it
should not be used as an benchmark for molecular methods of diagnosis.
One concern with using DNA-based molecular methods to detect
pathogen DNA directly from blood is that these assays can detect DNA from both
live and dead bacteria and cannot differentiate between them. This is of concern
because only the live bacteria are considered ‘clinically relevant’. I hypothesized
that the DNA in live cells would be associated with the pellet after centrifugation
of a blood sample, whereas the DNA from dead (lysed) cells would remain in the
plasma or supernatant fraction. The results showed that in all but one case there
was no additional information provided by the analysis of the plasma samples.
However, in one sample, which was determined by both the blood culture and
Gram-strain analysis and the MGS assay to contain a Gram-negative bacterial
pathogen, there was about three orders of magnitude more DNA in the plasma
sample than the blood pellet. These data suggest that this pathogen primarily
existed in the blood as lysed cells. This would suggest that the antimicrobial
treatment was working to control the infection; the outcome for this patient was
positive as he/she was released from the hospital. These experiments indicate
that my hypothesis was correct and that determining the DNA of both the plasma
and pellet fractions can have clinical relevance.
An important concern associated with using the 16S rRNA gene as an
assay target is that the assay is so sensitive that it can detect any bacterial DNA
that is present, including DNA contaminating the PCR and DNA extraction
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solutions. I addressed this issue by pretreating my qPCR mixes and DNA
extraction solutions with EMA. However, problems arose with the qPCR
amplification efficiency when EMA treatment was performed on the qPCR master
mix containing the probes. The reason for the EMS-sensitivity of the probes is
unclear. It was noted that the in the reactions the EMA-treated probes fluoresced
much less than the non-EMA treated probes. This issue was resolved by using
EMA-treated H2O to make the dilutions of the probes from the 100 uM and the 10
uM-working stock solutions. The probes were then added to the master mix after
the EMA treatment of the qPCR master mix. This eliminated the exposure of the
probes to EMA crosslinking and prevented the detection of contaminant DNA.
One surprising advantage to the extraction of small quantities of bacterial
DNA from blood samples is that the concurrent extraction of human DNA serves
as carrier DNA that increases the yield of the bacterial DNA. This became
obvious when we noted the much greater yield of DNA from blood compared to
PBS when each of the four control bacterial species were tested in blood
samples and PBS. The results from the DNA extracted from blood samples were
typically within one log of the input cell concentration used, whereas the DNA
extracted from PBS were consistently 2-logs lower than the input cell
concentration. The carrier DNA can also serve to dilute the bacterial DNA during
the DNA extraction procedure and therefore any small percentage loss in yield
would have significantly less impact on the overall amount of bacterial DNA that
is lost. As a result, I modified the DNA extraction from PBS by adding 200 ng of
yeast genomic DNA to act as carrier DNA. This improved the detection of our
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control organisms significantly. However, it did not significantly improve the
efficiency of the S. aureus DNA extraction from PBS.
Another surprising problem in our control experiments was associated with
the EMA treatment. I discovered that the MGS analysis of the S. aureus from the
blood was always one order of magnitude less than the input cells, whereas all of
the other three organisms were much more closely correlated to the amount of
input cells. The lower detection of S. aureus prompted a review of the literature,
which revealed that EMA had been shown previously to have adverse effects on
certain bacterial species (61, 62), including S. aureus. I performed experiments
evaluating the viability of our S. aureus strain after EMA exposure. I determined
that the EMA-treated PBS used in the washing and dilution steps was killing the
S. aureus cells. After switching to PMA for decontamination of the solutions to
which the live S. aureus cells were exposed, more consistent results were
observed for S. aureus. It is important to note that although this was important in
these control experiments in which live cells were added to blood and PBS, this
is not relevant to clinical samples as the DNA is already extracted from the cells
as a first step.
The MGS assay was developed based on the Gram status identification of
the 33 bacterial species commonly recovered in presumed septic patients in the
STICU of Memorial Herman Hospital in Houston, Texas. I am certain that a
greater range of pathogens would be common in different types of infections,
such as osteomyelitis. One strongpoint of the MGS assay is that it is easily
amendable to species not identified in its current configuration due to the low
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variability of the probe target sites. I expect that by adding a mixture of
degenerate probes containing single or double nucleotide substitutions for the
Gram-positive and Gram-negative probes, with all degenerate variations using
the same fluorophore, the assay’s species coverage could be greatly increased.
However, this addition to the assay requires experimental validation.
The MGS assay is currently configured as two duplex reactions that are
compared as ‘upstream’ and ‘downstream’ reactions in separate wells of a 96well assay plate. I plan that the final MGS assay will be configured as a
quadruplex reaction in which all four primers and all four probes are present in
one well. This configuration will create a situation in which the extension from
the forward primer from the upstream amplicon and the reverse primer from the
downstream amplicon will generate PCR products that I have termed the
‘flanking amplification’ products. These flanking products are of particular
concern because they are anticipated to use an abundance of reaction
components causing the amplification of the target amplicons to be less efficient.
I have addressed this concern by developing a ‘blocking’ oligonucleotide
containing phosphorothioate modifications that will anneal between the upstream
reverse primer and the downstream forward primer. This blocking
oligonucleotide will function to stop the extension of polymerase by forming a
stable duplex with the target site and preventing hydrolysis of the blocking oligo
by the phosphorothioate modifications. This technique has been tested in
standard PCR and shows great promise for further use (Fig. 19); however, a
quadruplex qPCR reaction is required for final testing.
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In summary, I have succeeded in the primary goal of this project, which
was to develop the Molecular Gram-stain assay to detect and determine the
Gram status of sepsis-associated bacterial pathogens. Based on previous
experiences in our laboratory I concluded that an ideal assay should contain
internal checks and balances, detect all bacteria by hybridization to a universally
conserved DNA region, and differentiate Gram status by hybridization to specific
DNA regions. I have developed a novel molecular diagnostic technology for the
detection of sepsis-associated infections. I have shown that this technology has
the ability to decrease the time to pathogen detection. It is anticipated that the
use of this MGS assay will provide an increase in the standard of septic patient
care, resulting in better patient outcomes with more rapid tailored antimicrobial
use for those with bone fide infections and removal of antimicrobial therapy from
those without infection.
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PERSPECTIVES
The development of new molecular techniques to diagnose infections is of
interest to academic and industrial communities alike. The current new
techniques include various methods of PCR analysis, mass spectroscopy,
automated microscopy, and NMR probe detection. The goal of this project was to
develop and validate a rapid, quantitative, and sensitive molecular assay for the
direct detection of pathogens in blood samples from suspected sepsis patients.
The bacterial 16S rRNA gene has been used commonly as a target for the
identification of bacterial genera and species. The MGS assay follows suit as it
is a method to detect bacterial pathogens and to differentiate their Gram-status.
However, it is not necessary to limit the use of this assay to detection alone. The
two amplicons (229 bp and 270 bp) can also be subjected to DNA sequence
analysis, which should be useful in identification of the genus and possibility
species of the pathogen if it is a single or predominant organism present in the
blood sample.
There are many options for downstream species identification with
species-specific probes. Additionally, I intend to develop a probe that will identify
the DNA of fungal pathogens to use along side the MGS assay.
Finally, although this molecular technology is an improvement upon the
current culture-based methods in that it is more rapid, sensitive and quantitative,
it does not currently provide information concerning antimicrobial susceptibility.
However, we anticipate that molecular technologies for identifying antibiotic
susceptibility genes and their activities will be further developed in the future.
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